What is the current stock price of HCW Biologics Inc. (HCWB)?

As of the latest market data, HCW Biologics Inc. (HCWB) is trading at $2.00. The stock has seen a loss of -23.63% today.

Does HCW Biologics Inc. (HCWB) pay a dividend?

Based on current data, HCW Biologics Inc. does not have a confirmed active dividend policy.

What is the market cap of HCW Biologics Inc.?

The current market capitalization of HCW Biologics Inc. (HCWB) is approximately unavailable.

HCW Biologics Inc. (HCWB) Stock Price, News & Key Metrics

globenewswire.com

6d ago

HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules

MIRAMAR, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune, cancer and senescence-associated dysplasia, today announced the pricing of its private placement of an aggregate of 2,846,975 units at a purchase price of $1.405 per unit priced at-the-market under Nasdaq rules to a group of healthcare investors (the “Investors”). Each unit consists of (i) one share of common stock at a purchase price of $1.28 per share (or, in lieu thereof, one pre-funded warrant at a purchase price of $1.2799 per pre-funded warrant with an exercise price of $0.0001 per share) and (ii) one warrant at a purchase price of $0.125 per warrant, each to purchase one share of common stock. The warrants will have an exercise price of $1.28 per share, will be exercisable immediately upon issuance, and will expire on the five and one-half year anniversary of the original issuance date. The shares of common stock (or pre-funded warrants) and the warrants comprising the units are immediately separable and will be issued separately in this offering. The closing of the offering is expected to occur on or about May 21, 2025, subject to the satisfaction of customary closing conditions.

HCWB

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement

HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules

HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session

HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement

HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules

HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session

HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies